BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Lantern Pharma Enrolls First Patient in Taiwan for Phase 2 Trial for Never-Smoker Lung Cancer

by Illia Petrov   •   Dec. 9, 2024  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Clinical Trials   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Following its recent expansion into Japan, Lantern Pharma has now dosed the first patient in Taiwan as part of its Phase 2 Harmonic clinical trial., evaluating LP-300 in never-smoker non-small cell lung cancer (NSCLC) patients who have relapsed after tyrosine kinase inhibitor (TKI) therapy.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

This expansion into East Asia includes sites in Japan and Taiwan, regions with higher rates of never-smoker NSCLC compared to Western populations. In Taiwan, over 50% of lung cancer cases occur in never-smokers, making it a key location for the trial.

LP-300 is a disulfide small molecule designed to modulate cellular redox pathways and inhibit tyrosine kinase oncogenes like EGFR, ALK, ROS, and MET-1, which are commonly mutated in never-smoker NSCLC. Early results from the U.S. safety lead-in cohort showed an 86% clinical benefit rate and a 43% objective response rate, demonstrating LP-300's potential to improve chemotherapy outcomes.

The Harmonic trial compares LP-300 combined with chemotherapy (pemetrexed and carboplatin) to chemotherapy alone. It aims to enroll 90 patients across multiple sites, focusing on endpoints like progression-free survival and overall survival. Lantern Pharma plans to evaluate interim data after 30 clinical events.

The trial is supported by Lantern Pharma’s RADR platform, which analyzes oncology data to identify promising therapeutic candidates. This AI-powered approach identified LP-300’s potential to address chemotherapy resistance, accelerating its development into clinical trials.

Lantern Pharma expects the trial to provide critical data supporting regulatory filings and the global need for targeted therapies in this distinct patient population.

Cover photo: RichieChan
Lantern Pharma

Topics: Clinical Trials   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.